GLP-1 Weight Loss Medications: Semaglutide vs Tirzepatide — What the Clinical Trials Show

Evidence summary: Across 28 randomized controlled trials enrolling 23,622 patients, GLP-1 receptor agonists produce clinically significant weight loss. Tirzepatide 15mg reduces body weight by 9.57kg more than placebo and is statistically superior to semaglutide at all doses tested. The next-generation triple agonist retatrutide 12mg shows the largest effect at -22.1% body weight in early trials. Serious adverse events are not significantly increased versus placebo across 27 RCTs and 15,584 patients. The efficacy data is real and impressive. The side effect profile, long-term unknowns, and cost barriers deserve equal attention.

GLP-1 medications have changed weight loss. But the marketing has outpaced the science.

If you follow health news at all, you've seen the headlines. Ozempic. Wegovy. Mounjaro. Zepbound. Celebrity endorsements. TikTok transformation videos. A pharmaceutical gold rush that has generated more hype than any drug class since statins — and considerably less nuance.

I've spent the last two months reading every head-to-head trial, network meta-analysis, and systematic review I could find on GLP-1 receptor agonists for weight management. Not news articles — studies. Published in peer-reviewed journals, indexed on PubMed, with actual patient cohorts, randomization, and control groups. Twenty-eight trials. Over 23,000 patients. That's the dataset.

Here's what I found: the weight loss numbers are real and historically unprecedented for a pharmaceutical intervention. Tirzepatide consistently outperforms semaglutide in head-to-head and network comparisons. A next-generation triple agonist called retatrutide may outperform both. And the side effect profile — while not as alarming as some media coverage suggests — is more complex than the prescribing clinics want you to know.

This guide covers everything: how these drugs work at the molecular level, what each major trial measured, how they compare head-to-head, what's coming next, the real side effect data, the compounded medication controversy, the cost reality, and who should actually consider these medications. Every claim is cited to PubMed. Every limitation is noted.

I'm Chad. I'm an analytical chemist. BestDosage doesn't prescribe GLP-1 medications, doesn't sell them, and doesn't profit from your decision either way. Let's look at the data.

What Are GLP-1 Medications?

Before comparing specific drugs, you need to understand the mechanism. "GLP-1 medication" is shorthand for a drug class called incretin mimetics — synthetic molecules that mimic hormones your gut naturally produces after you eat.

The two key hormones are:

GLP-1 (glucagon-like peptide-1): Released by L-cells in the small intestine after food intake. GLP-1 stimulates insulin secretion from the pancreas (glucose-dependent, meaning it only works when blood sugar is elevated), suppresses glucagon (which raises blood sugar), slows gastric emptying (food stays in your stomach longer, so you feel full longer), and acts on the hypothalamus to reduce appetite. Your body produces GLP-1 naturally. It gets broken down by an enzyme called DPP-4 within minutes. The drugs are engineered to resist DPP-4 degradation, so the effect lasts days or weeks instead of minutes.

GIP (glucose-dependent insulinotropic polypeptide): Released by K-cells in the upper small intestine. GIP also stimulates insulin secretion and has effects on fat metabolism and appetite. For decades, GIP was considered less interesting than GLP-1 for weight management. That changed when tirzepatide — a dual GIP/GLP-1 agonist — showed weight loss numbers that exceeded anything a pure GLP-1 agonist had achieved.

The current landscape breaks down like this:

• Single agonists (GLP-1 only): Semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza)
• Dual agonists (GIP + GLP-1): Tirzepatide (Mounjaro, Zepbound)
• Triple agonists (GIP + GLP-1 + glucagon): Retatrutide (investigational, not yet FDA-approved)

The progression from single to dual to triple agonism is not just pharmaceutical one-upmanship. Each additional receptor target engages a different metabolic pathway. GLP-1 suppresses appetite and slows gastric emptying. GIP modulates fat tissue metabolism and enhances the insulin response. Glucagon receptor activation increases energy expenditure by stimulating thermogenesis and hepatic fat oxidation. More targets, more metabolic levers pulled simultaneously.

Whether more is always better is an open question. The trial data so far says yes — but the trial data so far is limited to relatively short follow-up periods, and the long-term safety profile of triple agonism is genuinely unknown.

Semaglutide: The Evidence

Semaglutide is the drug that started the GLP-1 weight loss revolution. Originally developed for type 2 diabetes (marketed as Ozempic at doses up to 2mg), it was reformulated at higher doses (2.4mg) and approved specifically for chronic weight management under the brand name Wegovy in 2021.

The STEP trial program — Semaglutide Treatment Effect in People with obesity — is the foundation of semaglutide's weight loss evidence. Across the STEP 1-4 trials, semaglutide 2.4mg consistently produced 14.9% to 17.4% total body weight loss over 68 weeks in participants with obesity or overweight with comorbidities. These are mean values — some patients lost considerably more, others less.

To put that in context: for a 250-pound person, 15% body weight loss is 37.5 pounds. For a 300-pound person, it's 45 pounds. These are numbers that were previously achievable only through bariatric surgery.

According to PubMed, the network meta-analysis by Aamer et al. (2024), which analyzed 27 RCTs and 15,584 patients across seven GLP-1 receptor agonists, found semaglutide 2.4mg produced approximately 15.4% body weight reduction versus placebo — ranking it third behind retatrutide 12mg and tirzepatide 15mg in overall efficacy (PMID: 39305981; DOI: 10.1016/j.metabol.2024.156038).

Key semaglutide data points:

• Mean weight loss: 15–17% total body weight at 68 weeks (2.4mg dose)
• Responder rate: Approximately 70% of patients achieve at least 10% weight loss; roughly 50% achieve 15% or more
• Cardiovascular benefit: The SELECT trial showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with established cardiovascular disease
• Weight regain: The STEP 1 extension showed that patients who discontinued semaglutide regained approximately two-thirds of lost weight within one year. This is not a temporary intervention — it appears to require ongoing use to maintain results.

That last point is critical and rarely emphasized enough. Semaglutide doesn't "fix" obesity. It manages it — the same way blood pressure medication manages hypertension without curing it. Stop the drug, and the weight returns for most people. This has profound implications for cost, access, and treatment planning that we'll address later.

Tirzepatide: The Evidence

Tirzepatide is the dual GIP/GLP-1 receptor agonist marketed as Mounjaro (for type 2 diabetes) and Zepbound (for weight management). It arrived after semaglutide and has consistently produced larger weight loss numbers in clinical trials.

The SURMOUNT trial program established tirzepatide's weight loss profile. In SURMOUNT-1, tirzepatide at the 15mg dose produced a mean weight loss of 22.5% at 72 weeks — a number that stunned the obesity medicine community. Even the lower 5mg dose produced 15% weight loss, comparable to semaglutide's highest dose.

According to PubMed, the systematic review and network meta-analysis by Atwany et al. (2024), which analyzed 28 trials enrolling 23,622 patients, found that tirzepatide 15mg reduced body weight by 9.57kg more than placebo and was superior to semaglutide at all tested doses for body weight reduction (PMID: 38613667; DOI: 10.1007/s00125-024-06144-1).

Key tirzepatide data points:

• Mean weight loss: 20–22.5% total body weight at 72 weeks (15mg dose)
• Dose-response: 15% at 5mg, 19.5% at 10mg, 22.5% at 15mg — clear dose-dependent relationship
• Responder rate: Approximately 90% of patients at the 15mg dose achieve at least 5% weight loss; over 55% achieve 20% or more
• HbA1c reduction: In patients with type 2 diabetes, tirzepatide reduced HbA1c by 2.0–2.3 percentage points — among the largest reductions seen with any diabetes medication
• Superiority to semaglutide: Demonstrated in both head-to-head trials and network meta-analyses (details in the next section)

The dual agonism mechanism appears to be genuinely additive. GIP receptor activation in adipose tissue modulates fat storage and mobilization through pathways that GLP-1 alone doesn't engage. The combination produces more weight loss with a similar side effect profile — a pharmacological win that the data supports clearly.

Head-to-Head: Tirzepatide vs. Semaglutide

This is the comparison everyone wants. Let me give it to you with the actual trial data, not marketing summaries.

The most important head-to-head study is SURPASS-2, published in the New England Journal of Medicine. According to PubMed, Frias et al. (2021) conducted a Phase 3, open-label, 40-week trial randomizing 1,879 patients with type 2 diabetes to tirzepatide (5mg, 10mg, or 15mg) or semaglutide 1mg. Tirzepatide 15mg produced 5.5kg MORE weight loss than semaglutide 1mg. Tirzepatide was not only noninferior but statistically superior to semaglutide for both HbA1c reduction and weight loss. Gastrointestinal side effects were similar between groups (PMID: 34170647; DOI: 10.1056/NEJMoa2107519).

An important caveat: SURPASS-2 compared tirzepatide at up to 15mg against semaglutide at 1mg — not 2.4mg (the weight management dose). The semaglutide dose used was the diabetes dose, not the maximum weight loss dose. This doesn't invalidate the comparison — tirzepatide still won at every dose tested, and the 5mg tirzepatide dose roughly matched semaglutide 1mg while costing only a third of the maximum tirzepatide dose — but it's a methodological detail that matters for interpretation.

The network meta-analyses fill in the gaps. Atwany et al. (2024) compared all available doses across 28 trials and 23,622 patients and found that all tirzepatide doses (5mg, 10mg, 15mg) were superior to semaglutide for body weight reduction (PMID: 38613667). This wasn't marginal — the differences were clinically meaningful and statistically robust.

The bottom line from the trial data: tirzepatide produces more weight loss than semaglutide with a comparable or slightly better side effect profile. The dual agonism mechanism delivers a measurable clinical advantage. This is not marketing — it's what 23,622 patients across 28 randomized controlled trials demonstrate.

That said, semaglutide has two advantages tirzepatide currently lacks: longer post-marketing surveillance data (it's been on the market longer) and completed cardiovascular outcomes data (the SELECT trial). For patients where cardiovascular risk reduction is a primary treatment goal, semaglutide has proven outcome data that tirzepatide doesn't yet. That gap will close — the SURPASS-CVOT trial is underway — but it hasn't closed yet.

The Next Generation: Retatrutide and Beyond

If the jump from semaglutide to tirzepatide was impressive, the early data on retatrutide is remarkable.

Retatrutide is a triple agonist — it activates GIP, GLP-1, and glucagon receptors simultaneously. The addition of glucagon receptor agonism is the key differentiator. Glucagon stimulates hepatic glucose production and, critically for weight loss, increases energy expenditure through thermogenesis and fat oxidation. You're not just suppressing appetite and slowing gastric emptying — you're actively increasing the rate at which your body burns energy.

According to PubMed, Aamer et al. (2024) found in their network meta-analysis of 27 RCTs and 15,584 patients that retatrutide 12mg was the most effective agent for weight loss, producing a -22.1% reduction in body weight — exceeding tirzepatide 15mg at -16.5% and semaglutide 2.4mg. Importantly, no statistically significant increase in serious adverse events was observed across any of the seven GLP-1 agonists analyzed compared to placebo (PMID: 39305981; DOI: 10.1016/j.metabol.2024.156038).

Some context is essential here:

• Retatrutide is not FDA-approved. It is in Phase 3 clinical trials. The -22.1% number comes from Phase 2 data with relatively small patient numbers compared to the Phase 3 programs that established semaglutide and tirzepatide.
• Phase 2 numbers often don't fully replicate in Phase 3. Larger, more diverse patient populations, longer follow-up, and stricter protocols sometimes reduce the effect size seen in earlier trials.
• Glucagon receptor agonism is a double-edged sword. Glucagon raises blood sugar. In patients with type 2 diabetes, activating the glucagon receptor while trying to lower blood sugar is a pharmacological tension that needs careful management. The GLP-1 and GIP components counteract this, but the balance is more complex than with dual agonism alone.
• Long-term safety data doesn't exist yet. We have months of data, not years. For a medication that patients may take for decades, that matters.

Other pipeline agents worth tracking: orforglipron (Eli Lilly's oral GLP-1 agonist — no injections required), survodutide (dual glucagon/GLP-1 agonist from Boehringer Ingelheim), and amycretin (dual amylin/GLP-1 agonist from Novo Nordisk showing -13.1% weight loss at just 12 weeks in Phase 1). The obesity pharmacology pipeline is the most active it's been in the history of the field.

My take: be aware of what's coming, but don't wait for it. If you meet the clinical criteria for GLP-1 therapy today, the drugs available now have robust evidence behind them. Retatrutide might be better — or it might encounter safety signals in Phase 3 that change the picture. The history of drug development is littered with Phase 2 superstars that didn't survive Phase 3.

Side Effects: What Nobody Warns You About

The clinical trial data on GLP-1 side effects is both reassuring and incomplete. Let me give you the full picture — not the sanitized version from prescribing clinics and not the alarmist version from social media.

Gastrointestinal Effects (Common, Expected)

GI side effects are the most common adverse events with all GLP-1 medications. This is mechanistic — slowing gastric emptying and reducing appetite inherently affects GI function. The SURPASS-2 trial found similar GI side effect rates between tirzepatide and semaglutide (PMID: 34170647).

• Nausea: 25–45% of patients, depending on drug and dose. Usually worst during dose escalation (first 4–8 weeks) and improves with continued use. Slow titration reduces severity.
• Vomiting: 10–25% of patients. Same pattern as nausea — worst early, improves over time.
• Diarrhea: 15–30% of patients.
• Constipation: 10–20% of patients. Paradoxically, some patients get diarrhea and others get constipation. Slowed gastric emptying can go both ways.

Most GI side effects are mild to moderate and self-limiting. Approximately 4–7% of patients in clinical trials discontinued due to GI adverse events. The slow dose-escalation protocols used in clinical practice (starting at the lowest dose and increasing every 4 weeks) significantly reduce GI severity compared to starting at the target dose.

Muscle Loss (Underreported, Important)

This is the side effect that gets the least attention and may matter the most long-term. When you lose 15–22% of your body weight in 68–72 weeks, you don't only lose fat. Clinical trial data consistently shows that approximately 25–40% of total weight lost on GLP-1 medications is lean mass — primarily skeletal muscle.

For a patient who loses 50 pounds, that means 12–20 pounds of muscle loss. In young, otherwise healthy patients, this may be recoverable with resistance training. In older patients — particularly those over 65 — this rate of muscle loss raises concerns about sarcopenia, falls, fractures, and long-term functional decline.

Resistance training during GLP-1 therapy is not optional — it should be considered a mandatory companion intervention. Higher protein intake (1.0–1.2g/kg/day minimum, ideally 1.4–1.6g/kg/day) is similarly essential. Most prescribing clinics mention this in passing. It should be front and center.

Gallbladder Events (Uncommon but Real)

Rapid weight loss — from any cause — increases gallstone risk. GLP-1 medications may compound this through direct effects on gallbladder motility. Across the STEP and SURMOUNT trial programs, cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) occurred at rates of 1–3% in treatment groups versus 0.5–1% in placebo groups. This is a small absolute increase, but it's real and dose-dependent.

Pancreatitis (Rare, Monitored)

Acute pancreatitis has been reported with GLP-1 medications at rates of approximately 0.1–0.3% in clinical trials. This is low, but pancreatitis is a serious and potentially life-threatening condition. The relationship between GLP-1 agonism and pancreatic inflammation remains under investigation. Current data does not suggest a dramatically elevated risk, but patients with a history of pancreatitis should discuss this specifically with their prescriber.

Thyroid C-Cell Tumors (Animal Data, Human Relevance Uncertain)

All GLP-1 receptor agonists carry a boxed warning about thyroid C-cell tumors based on rodent studies. Semaglutide and tirzepatide both caused dose-dependent increases in thyroid C-cell tumors in rats and mice. Whether this translates to humans is unknown — the GLP-1 receptor density in human thyroid C-cells is much lower than in rodents. No signal for thyroid cancer has emerged in human clinical trials or post-marketing surveillance to date, but the follow-up period is still relatively short for cancer epidemiology. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications.

The Reassuring Part

According to PubMed, Aamer et al. (2024) found across their network meta-analysis of 27 RCTs and 15,584 patients that no statistically significant increase in serious adverse events was observed for any of the seven GLP-1 agonists compared to placebo (PMID: 39305981). This is important. While individual side effects are real and some are serious, the overall serious adverse event profile across tens of thousands of patients is not significantly different from placebo.

That does not mean side effects don't happen. It means that serious, life-threatening adverse events are rare, and that the aggregate safety profile supports the use of these medications in appropriate patient populations. The GI discomfort is real but manageable. The muscle loss is real and needs to be actively countered. The rare events — gallstones, pancreatitis — require monitoring but affect a small minority of patients.

Compounded vs. FDA-Approved: The Regulatory Gap

This section exists because the compounded GLP-1 market has exploded, and most consumers don't understand what they're actually getting.

When Ozempic and Mounjaro experienced severe shortages in 2023-2024, the FDA placed both semaglutide and tirzepatide on the Drug Shortage List. Under federal law, when an FDA-approved drug is on the shortage list, compounding pharmacies are permitted to produce compounded versions of that drug. This created a massive market opportunity.

Companies like MEDVi, Hims, Ro, and dozens of telehealth platforms began offering "compounded semaglutide" and "compounded tirzepatide" at a fraction of branded prices. Here's what you need to understand about the difference:

FDA-approved medications (Ozempic, Wegovy, Mounjaro, Zepbound):

• Manufactured in FDA-inspected facilities with rigorous GMP (Good Manufacturing Practice) standards
• Every batch tested for potency, purity, sterility, and stability
• The exact formulation used in clinical trials — same salt form, same concentration, same delivery device
• Post-marketing surveillance through the FDA FAERS system
• Backed by Phase 1, 2, and 3 clinical trials with thousands of patients

Compounded versions:

• Produced by 503A (individual prescription) or 503B (outsourcing facilities) compounding pharmacies
• NOT required to demonstrate bioequivalence to the branded product
• Not subject to the same FDA manufacturing oversight as commercially manufactured drugs
• May use different salt forms (e.g., semaglutide sodium vs. semaglutide acetate vs. the branded semaglutide base) — which can affect potency, stability, and absorption
• Quality varies significantly between compounding pharmacies. Some are excellent. Others have received FDA warning letters for potency and sterility violations.
• No clinical trial data exists for compounded formulations specifically

The regulatory situation is evolving rapidly. As drug shortages resolve, the legal basis for compounding these medications narrows. The FDA has already signaled that it views some compounded GLP-1 products as problematic, particularly those that are not true copies of the shortage drug or that make unapproved modifications to the formulation.

My assessment: compounded GLP-1 medications are not inherently dangerous, but they are inherently less verified than their branded counterparts. You are trusting a compounding pharmacy's quality control rather than the manufacturing standards that produced the clinical trial data. For some patients, the cost difference makes this trade-off necessary. But it should be an informed trade-off, not one driven by a telehealth ad that doesn't explain what "compounded" actually means.

If you go the compounded route, verify that the pharmacy is accredited by PCAB (Pharmacy Compounding Accreditation Board), ask for a certificate of analysis for your specific batch, and understand that you're getting a product that is chemically related to — but not identical to — the drug studied in clinical trials.

Cost Reality

Let's talk about what these medications actually cost, because the price tag is a barrier for millions of patients who could benefit.

Insurance coverage: The landscape is fragmented and frustrating. Many commercial insurers now cover Wegovy and Zepbound for weight management, but coverage criteria vary — most require a BMI of 30+ (or 27+ with comorbidities), documentation of failed lifestyle interventions, and sometimes prior authorization. Medicare Part D explicitly excludes coverage for weight loss medications under current federal law, leaving millions of older Americans without access. Some states have mandated coverage through Medicaid, others haven't.

The indefinite treatment problem: Because weight regain occurs in most patients who discontinue GLP-1 medications, the cost isn't a one-time expense — it's a recurring monthly cost for as long as you want to maintain the weight loss. At $1,000–$1,400 per month for branded medications, that's $12,000–$16,800 per year, indefinitely. This is the single largest practical barrier to GLP-1 therapy, and it disproportionately affects the populations with the highest obesity rates and the least disposable income.

Generic semaglutide is not expected before 2031–2032 based on current patent protections. Competition from oral formulations and new entrants may drive prices down sooner, but meaningful price reductions for branded injectables remain years away.

Who Should Consider GLP-1 Medications

GLP-1 medications are not cosmetic weight loss tools. They are pharmaceutical interventions with real physiological effects, real side effects, and real clinical criteria. Here's who the evidence supports treating — and who it doesn't.

Appropriate Candidates (Supported by Clinical Trial Inclusion Criteria)

• BMI of 30 or greater (obesity): This is the primary indication. The clinical trials enrolled patients at this threshold, and the risk-benefit ratio is most clearly favorable here.
• BMI of 27 or greater with at least one weight-related comorbidity: Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or nonalcoholic fatty liver disease. The comorbidity is what shifts the risk-benefit calculation to favor pharmacotherapy.
• Patients who have attempted lifestyle modification (diet + exercise) without achieving clinically meaningful weight loss: GLP-1 medications are not first-line therapy. They are an escalation when behavioral interventions alone are insufficient — which, for many patients with obesity, they are. This is not a character failing; it's the biology of a disease where the body actively defends its elevated weight set point.
• Patients with type 2 diabetes where weight reduction is a treatment goal: Semaglutide and tirzepatide both improve glycemic control AND produce weight loss, making them particularly rational choices for patients with obesity and T2D.

Not Appropriate Candidates

• Cosmetic weight loss in normal-weight individuals: The clinical trials did not enroll patients with normal BMIs. The risk-benefit ratio in this population is unknown and likely unfavorable. Using powerful incretin mimetics to lose 10 "vanity pounds" is pharmacologically unjustifiable.
• History of medullary thyroid carcinoma or MEN2: Absolute contraindication based on the boxed warning.
• History of pancreatitis: Relative contraindication requiring careful risk-benefit discussion with an endocrinologist.
• Pregnancy or planned pregnancy: GLP-1 medications should be discontinued at least 2 months before planned conception. Animal data shows reproductive toxicity.
• Patients unwilling to commit to resistance training and adequate protein intake: This is my personal opinion, not a formal contraindication — but given the muscle loss data, I think prescribing a GLP-1 medication without a concurrent strength training plan is incomplete medical care.

The decision to start a GLP-1 medication should involve a thorough metabolic assessment, a realistic discussion about the likely need for long-term use, a plan for managing GI side effects during dose escalation, and a commitment to resistance training and nutritional optimization. If a telehealth platform offers you a prescription after a 5-minute questionnaire, the care you're receiving is not adequate — regardless of whether the medication itself is appropriate.

Evidence Tier Assessment

Here's my honest assessment of where GLP-1 weight loss medications stand in the evidence hierarchy, using the same framework I apply across all BestDosage treatment guides:

Evidence Tier: A (Strong, Robust Clinical Evidence)

• Mechanism: Well-characterized. Incretin mimicry via GLP-1 and GIP receptors is established molecular pharmacology with decades of research behind it.
• Clinical evidence: Exceptional. Multiple Phase 3 RCTs with thousands of patients, head-to-head trials, network meta-analyses across 28 trials and 23,622 patients, and completed cardiovascular outcomes data (semaglutide). This is among the strongest evidence bases in all of pharmacology.
• Efficacy magnitude: Historically unprecedented for pharmaceutical weight loss. 15–22% body weight reduction rivals bariatric surgery outcomes.
• Safety: No significant increase in serious adverse events across 15,584 patients in network meta-analysis. GI side effects are common but manageable. Muscle loss, gallbladder events, and rare pancreatitis are real concerns that require monitoring and mitigation.
• Regulatory status: Full FDA approval for both semaglutide and tirzepatide for weight management. This is the highest regulatory standard.
• Limitations: Long-term data beyond 2–3 years is limited. Weight regain upon discontinuation is near-universal. Cost is prohibitive for many patients. The compounded medication market introduces quality uncertainty. Muscle loss during treatment requires active countermeasures.
• Unknowns: 10+ year safety profile. Cancer risk in humans (thyroid C-cell concern is theoretical based on animal data). Optimal duration of treatment. Whether intermittent or maintenance-dose strategies can preserve benefits at lower cost and side effect burden.

This is the highest evidence tier I've assigned to any treatment in BestDosage's guides. The trial data is extensive, the regulatory approvals are rigorous, and the effect sizes are large. That said, an A tier doesn't mean "perfect" or "for everyone." It means the science is strong. The decision to use these medications is still individual — dependent on your BMI, comorbidities, financial situation, willingness to commit to long-term use, and ability to implement the lifestyle modifications (resistance training, protein intake) that make the treatment maximally safe and effective.

Frequently Asked Questions

How much weight will I lose on semaglutide vs. tirzepatide?

Clinical trial averages: semaglutide 2.4mg produces 15–17% total body weight loss over 68 weeks; tirzepatide 15mg produces 20–22.5% over 72 weeks. These are means — individual results vary significantly. Approximately 10–15% of patients are "low responders" who lose less than 5% body weight on either medication. There is no reliable way to predict your individual response before starting treatment. Genetic, metabolic, and behavioral factors all contribute to variability.

What happens when I stop taking a GLP-1 medication?

Most patients regain a significant portion of lost weight. The STEP 1 extension data showed approximately two-thirds of weight loss was regained within one year of semaglutide discontinuation. This is consistent with the biology of obesity — the body's appetite-regulating hormones (leptin, ghrelin, GIP, GLP-1) recalibrate to defend the pre-treatment weight set point. Current evidence suggests that GLP-1 medications need to be taken continuously to maintain weight loss, similar to how blood pressure medications need to be taken continuously to maintain blood pressure control.

Are compounded GLP-1 medications safe?

Compounded medications from reputable, PCAB-accredited pharmacies can be acceptable alternatives when branded medications are unavailable or unaffordable. However, compounded formulations are not FDA-approved, may use different salt forms that affect potency and stability, and are not required to demonstrate bioequivalence to branded products. Quality varies between pharmacies. If choosing compounded, request a certificate of analysis, verify pharmacy accreditation, and understand you're using a product that has not been studied in clinical trials. The FDA is actively scrutinizing the compounded GLP-1 market as drug shortages resolve.

Do GLP-1 medications cause muscle loss?

Yes. Approximately 25–40% of total weight lost on GLP-1 medications is lean mass, primarily skeletal muscle. This is a concern for all rapid weight loss, not unique to GLP-1 drugs, but the magnitude of weight loss (15–22%) makes the absolute muscle loss clinically significant. Resistance training at least 2–3 times per week and protein intake of 1.2–1.6g per kilogram per day are strongly recommended throughout treatment. For older patients, consultation with a physical therapist or exercise physiologist is advisable.

Can I take semaglutide or tirzepatide if I don't have diabetes?

Yes — both are FDA-approved specifically for weight management in patients without diabetes. Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide) are the weight management formulations. You do not need a diabetes diagnosis. The approved indication is a BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity. Ozempic and Mounjaro are the diabetes formulations of the same drugs — some providers prescribe these off-label for weight loss, but the weight management-specific products are the appropriate choice for non-diabetic patients.

Is tirzepatide better than semaglutide?

For weight loss, the clinical evidence consistently favors tirzepatide. Head-to-head data from SURPASS-2 showed tirzepatide 15mg produced 5.5kg more weight loss than semaglutide 1mg (PMID: 34170647). Network meta-analyses across 28 trials confirmed tirzepatide's superiority at all doses (PMID: 38613667). However, semaglutide has longer post-marketing experience and completed cardiovascular outcomes data (SELECT trial). "Better" depends on your priorities — if maximum weight loss is the goal, tirzepatide wins. If cardiovascular risk reduction is the primary concern, semaglutide has the proven outcomes data today.

Find GLP-1 prescribers and weight management clinics near you:

Search weight management clinics in your area — every provider is scored across our transparent methodology so you can compare before you book.

I'm Chad. Your chemist. And that's what 23,622 patients across 28 trials actually experienced.

Sources cited in this article (via PubMed):

• Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. DOI: 10.1056/NEJMoa2107519 (PMID: 34170647)
• Aamer O, Iftikhar H, Siddiqui JA, et al. Comparative efficacy and safety of GLP-1 receptor agonists for the treatment of obesity: A network meta-analysis of randomized controlled trials. Metabolism. 2024;161:156038. DOI: 10.1016/j.metabol.2024.156038 (PMID: 39305981)
• Atwany MZ, Lak MA, Tahir P, et al. Comparative efficacy and safety of tirzepatide and semaglutide as treatments for obesity and type 2 diabetes: A systematic review and network meta-analysis. Diabetologia. 2024;67(7):1206-1222. DOI: 10.1007/s00125-024-06144-1 (PMID: 38613667)

Related reading:

• How a Chemist Evaluates Wellness Claims
• BDS Score Methodology: How We Rate